Phase 2 study for people with Friedreich Ataxia

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Design Therapeutics, Inc.
Registry number NCT06874010
Started 1 June 2025 Today 16 October 2026 Estimated completion 1 December 2026

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Scientia Clinical Research Ltd Sydney NSW Recruiting
Doherty Clinical Trials East Melbourne VIC Recruiting
Nucleus Network Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 65 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 20

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Participants must be 18-65 years of age inclusive, at the time of signing the informed consent.

* Genetically confirmed diagnosis of FA, with homozygous GAA repeat expansions in the frataxin gene.

* Stage 5.5 or less on the FSA at screening.

* BMI between 16 and 32 kg/m2 at screening; weight should be \<= 100 kg at screening.

* Male and/or female using protocol defined and regulatory approved contraception.

* Capable of giving signed informed consent.

Exclusion Criteria:

* Any concomitant medical condition that in the opinion of the investigator, puts the participant at risk or precludes participant from completing the study protocol.

* Any clinically significant nonmedical conditions and psychiatric disorders that could put the participant at higher risk for participation in the study, influence the participant's ability to participate in the study, or interfere with interpretation of the participant's study results, in the opinion of the investigator.

* Received an investigational agent within the last 30 days or 5 half-lives, whichever longer, prior to the first dose of study drug, or are in follow-up of another clinical study prior to study enrollment. Exception: Potential participants who are currently on Omaveloxolone must be on stable doses for at least 3 months.

* Is not willing to comply with the contraceptive requirements during the study period, as per protocol.

Dates on the record

Started 1 June 2025
Estimated completion 1 December 2026
Registry last updated 18 May 2025
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 18 May 2025.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.